JANUVIA™, First In New Class Of Oral Treatments Known As DPP-4 Inhibitors, Recommended For Approval For The Treatment Of Type 2 Diabetes, EU

... JANUVIA™ (sitagliptin phosphate), Merck & Co., Inc.'s treatment for patients with type 2 diabetes, today received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) in Europe. The CHMP opinion recommends that JANUVIA be approved in the European Union for the treatment of type 2 diabetes. [click link for full article] ...